About Enoyl-CoA hydratase domain-containing protein 3, mitochondrial
Enoyl-CoA hydratase domain-containing protein 3, mitochondrial (ECHDC3) is a protein
from Homo sapiens identified by UniProt accession
Q96DC8, 303 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Enoyl-CoA hydratase domain-containing protein 3, mitochondrial |
|---|
| UniProt accession | Q96DC8 |
|---|
| Gene | ECHDC3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 303 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (54)
Diseases linked to this target (Open Targets).
- white matter hyperintensity measurement · score 0.46
- Alzheimer disease · score 0.43
- mean platelet volume · score 0.43
- protein measurement · score 0.40
- family history of Alzheimer’s disease · score 0.39
- platelet count · score 0.37
- late-onset Alzheimers disease · score 0.36
- balding measurement · score 0.27
- platelet crit · score 0.26
- acute myeloid leukemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96DC8-F1 | alphafold | PREDICTED | 90.28 | — |
Amino-acid sequence (303 residues)
MAAVAVLRAF GASGPMCLRR GPWAQLPARF CSRDPAGAGR RESEPRPTSA RQLDGIRNIV LSNPKKRNAL SLAMLKSLQS DILHDADSND LKVIIISAEG PVFSSGHDLK ELTEEQGRDY HAEVFQTCSK VMMHIRNHPV PVIAMVNGLA AAAGCQLVAS CDIAVASDKS SFATPGVNVG LFCSTPGVAL ARAVPRKVAL EMLFTGEPIS AQEALLHGLL SKVVPEAELQ EETMRIARKI ASLSRPVVSL GKATFYKQLP QDLGTAYYLT SQAMVDNLAL RDGQEGITAF LQKRKPVWSH EPV
Explore Enoyl-CoA hydratase domain-containing protein 3, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets